NKGen

Natural killer cells
#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

Positive early data for Alzheimer’s natural killer cell therapy

NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD). An early independent review of the Phase I data shows that after three months treatment with… Read More

#Editor's Choice #News

#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

The killer instinct: Using natural killer therapy to treat Alzheimer’s

DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech… Read More

#Exclusive Content